Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 ...

Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, presented the results of the CEPHEUS trial and emphasized the positive impact ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...